Molnupiravir is currently being developed by Merck & Co. Inc. in collaboration with Ridgeback Biotherapeutics, which licensed the drug from DRIVE (founded by Emory chemist Dennis Liotta) in 2020. It could be the first oral antiviral medicine to treat COVID-19. Continue readingMolnupiravir and Drug Development at Emory
Categories